Medicare Enrolled

Dr. Petros Grivas, M.D.

Medical Oncology · Seattle, WA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
825 EASTLAKE AVE E, Seattle, WA 98109
2065205000
Registered in NPPES since 2008
NPI: 1740443852 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Grivas from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Grivas? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Grivas

Dr. Petros Grivas is a medical oncology specialist in Seattle, WA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Grivas performed 178 Medicare services in 2023. These records do not provide a deduplicated patient total.

Between the years covered by Open Payments, Dr. Grivas received a total of $597,041 from 39 pharmaceutical and/or device companies across 435 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Grivas is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years of NPI registration ▲ 178 Medicare services $597,041 industry payments

Medicare Practice Summary — 2023

Medicare Utilization ↗
178
Medicare services
Bottom 22% in WA for medical oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
Not available
Unique patients (not deduplicated)
$124
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
157 $119 $371
New patient office visit, complex (60-74 min) 21 $155 $507
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.

Industry Payment Transparency

Open Payments through 2024 ↗
$597,041
Total received (2018-2024)
Avg $85,292/year across 7 years
Top 3% in WA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
39
Companies
435
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$91,572
2023
$52,325
2022
$98,602
2021
$122,958
2020
$78,217
2019
$84,273
2018
$69,093

Payments by company (2024)

Gilead Sciences, Inc.
$41,497
Merck Sharp & Dohme LLC
$11,237
E.R. Squibb & Sons, L.L.C.
$9,273
Merck KGaA
$8,250
PFIZER INC.
$5,657
ABBVIE INC.
$3,491
Daiichi Sankyo Inc.
$3,425
AstraZeneca Pharmaceuticals LP
$3,398
AstraZeneca UK Limited
$2,055
EMD Serono Research & Development Institute, Inc.
$1,500
Astellas Pharma Global Development
$1,250
F. Hoffmann-La Roche AG
$380
Exelixis Inc.
$137
Ferring Pharmaceuticals Inc.
$22
Top 3 companies account for 67.7% of 2024 payments
All-time payments by company (2018-2024) ›
EMD Serono, Inc.
$101,748
Gilead Sciences, Inc.
$77,641
PFIZER INC.
$55,326
AstraZeneca Pharmaceuticals LP
$41,504
Seagen Inc.
$38,400
Merck KGaA
$34,500
AstraZeneca UK Limited
$32,052
Merck Sharp & Dohme Corporation
$30,938
E.R. Squibb & Sons, L.L.C.
$29,366
Merck Sharp & Dohme LLC
$22,330
Janssen Biotech, Inc.
$16,360
Seattle Genetics, Inc.
$15,218
F. Hoffmann-La Roche AG
$12,168
Janssen Global Services, LLC
$9,472
Astellas Pharma Global Development
$8,143
Regeneron Pharmaceuticals, Inc.
$6,878
UROGEN PHARMA, INC.
$6,400
Janssen Research & Development, LLC
$6,200
Exelixis Inc.
$6,156
Ares Trading SA
$4,875
Janssen Scientific Affairs, LLC
$4,145
GlaxoSmithKline, LLC.
$3,929
ABBVIE INC.
$3,491
G1 Therapeutics, Inc.
$3,480
Daiichi Sankyo Inc.
$3,425
Clovis Oncology, Inc.
$3,262
GENZYME CORPORATION
$3,128
EMD Serono Research & Development Institute, Inc.
$3,000
Fresenius Kabi USA, LLC
$2,782
Genentech, Inc.
$2,724
Merck, S.L.U.
$2,250
Heron Therapeutics, Inc.
$1,842
Foundation Medicine, Inc.
$1,205
Incyte Corporation
$1,125
Aadi Bioscience, Inc.
$1,000
Photocure Inc
$310
Genentech USA, Inc.
$219
Astellas Pharma US Inc
$28
Ferring Pharmaceuticals Inc.
$22
Top 3 companies account for 39.3% of all-time payments
Associated products mentioned in payments ›
ADSTILADRIN · ATACAND · Avastin · BALVERSA · BAVENCIO · Balversa · Bavencio · CABOMETYX · COSELA · Cabometyx · Cysview · Erleada · FOUNDATIONACT · FOUNDATIONONE LIQUID · FYARRO · IMFINZI · INLYTA · JELMYTO · JEVTANA · KEYTRUDA · LENVIMA · LIBTAYO · LYNPARZA · OPDIVO · PADCEV · Padcev · Rubraca · SUSTOL · Stimufend · TECENTRIQ · Trodelvy · XTANDI
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for a medical oncology specialist in Seattle?
Compare medical oncologists in the Seattle area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists in nearby ZIP areas
97
County median income
$122,148
Nearest hospital to ZIP centroid (approximate)
VIRGINIA MASON MEDICAL CENTER
1.4 mi

Data Sources

Provider Registry NPPES NPPES snapshot; verify current record
Medicare Enrollment PECOS PECOS snapshot
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Grivas is a clinical cardiology specialist, with moderate Medicare volume, with 18 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Grivas experienced with office visit, established patient, complex (40-54 min)?
Based on Medicare claims data, Dr. Grivas performed 157 office visit, established patient, complex (40-54 min) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Grivas receive payments from pharmaceutical companies?
Yes. Dr. Grivas received a total of $597,041 from 39 companies across 435 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Grivas's costs compare to other medical oncologists in Seattle?
Dr. Grivas's average Medicare payment per service is $124. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Grivas) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →